Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells 50,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 50,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total value of $374,000.00. Following the transaction, the chief executive officer now owns 758,738 shares in the company, valued at approximately $5,675,360.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Christopher Gibson also recently made the following trade(s):

• On Wednesday, June 5th, Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.42, for a total value of $421,000.00.
• On Wednesday, May 1st, Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.73, for a total value of $386,500.00.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $8.36 on Monday. The stock’s fifty day moving average price is $8.71 and its two-hundred day moving average price is $9.77. The company has a market cap of $1.99 billion, a PE ratio of -5.22 and a beta of 0.83. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm had revenue of $13.80 million for the quarter, compared to the consensus estimate of $11.10 million. During the same quarter last year, the business posted ($0.34) EPS. The company’s revenue was up 14.0% compared to the same quarter last year. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on RXRX shares. Needham & Company LLC reissued a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th. KeyCorp reduced their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $26,000. National Bank of Canada FI boosted its holdings in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after acquiring an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $47,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares in the last quarter. Finally, Oxford Wealth Group LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $106,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.